Postbiotics: Modulation of the Gut Microbiota and Potential for Association with Nanotechnology.

IF 4.4 2区 生物学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Ana Júlia Rocha Cardoso, Suzana Gonçalves Carvalho, Vitória Ribeiro Mantovanelli, Leonardo de Freitas Marinho, Amanda Letícia Polli Silvestre, Tânia Forster-Carneiro, Maria Palmira Daflon Gremião, Marlus Chorilli
{"title":"Postbiotics: Modulation of the Gut Microbiota and Potential for Association with Nanotechnology.","authors":"Ana Júlia Rocha Cardoso, Suzana Gonçalves Carvalho, Vitória Ribeiro Mantovanelli, Leonardo de Freitas Marinho, Amanda Letícia Polli Silvestre, Tânia Forster-Carneiro, Maria Palmira Daflon Gremião, Marlus Chorilli","doi":"10.1007/s12602-025-10675-3","DOIUrl":null,"url":null,"abstract":"<p><p>Postbiotics are preparations containing inanimate microorganisms or their components that have a direct or indirect beneficial effect on the host and can include many different components, such as short-chain fatty acids, bacterial lysates, cell-free culture supernatants, cell wall fragments, enzymes, and exopolysaccharides. Despite the numerous advantages of postbiotics for the body, their use is limited due to unfavorable pharmacokinetics, low bioavailability, non-selective pharmacological action, poor palatability, and unpleasant odor. The development of nanotechnology-based delivery systems could be an important industrial tool to enhance the selective action of these agents and improve their therapeutic efficacy, particularly in the pharmaceutical and food sectors. In the pharmaceutical industry, several nanotechnology-based delivery systems have already been approved by the FDA and successfully marketed, demonstrating their clinical and industrial viability, such as Abraxane®, Doxil® (or Caelyx®), Onivyde®, Marqibo®, and Vyxeos®. In the food industry, products such as Driphorm® (nanostructured lipid emulsion for the efficient delivery of vitamin D in food) illustrate how nanotechnology has been applied in concrete ways to the development of functional foods and nutraceuticals, contributing to technological innovation, added value, and advances in health promotion. However, although nanotechnology in the delivery of postbiotics is an emerging and innovative field with promising preclinical studies, the lack of consolidated clinical or commercial data means that this topic needs to be expanded in order to achieve standardization and clinical validation. This review aims to highlight the importance of postbiotics in the modulation of gut microbiota and in the prevention/treatment of disease, as well as the potential of using nanotechnology to facilitate the targeting of these compounds and the limitations of using these systems for such applications.</p>","PeriodicalId":20506,"journal":{"name":"Probiotics and Antimicrobial Proteins","volume":" ","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Probiotics and Antimicrobial Proteins","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1007/s12602-025-10675-3","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Postbiotics are preparations containing inanimate microorganisms or their components that have a direct or indirect beneficial effect on the host and can include many different components, such as short-chain fatty acids, bacterial lysates, cell-free culture supernatants, cell wall fragments, enzymes, and exopolysaccharides. Despite the numerous advantages of postbiotics for the body, their use is limited due to unfavorable pharmacokinetics, low bioavailability, non-selective pharmacological action, poor palatability, and unpleasant odor. The development of nanotechnology-based delivery systems could be an important industrial tool to enhance the selective action of these agents and improve their therapeutic efficacy, particularly in the pharmaceutical and food sectors. In the pharmaceutical industry, several nanotechnology-based delivery systems have already been approved by the FDA and successfully marketed, demonstrating their clinical and industrial viability, such as Abraxane®, Doxil® (or Caelyx®), Onivyde®, Marqibo®, and Vyxeos®. In the food industry, products such as Driphorm® (nanostructured lipid emulsion for the efficient delivery of vitamin D in food) illustrate how nanotechnology has been applied in concrete ways to the development of functional foods and nutraceuticals, contributing to technological innovation, added value, and advances in health promotion. However, although nanotechnology in the delivery of postbiotics is an emerging and innovative field with promising preclinical studies, the lack of consolidated clinical or commercial data means that this topic needs to be expanded in order to achieve standardization and clinical validation. This review aims to highlight the importance of postbiotics in the modulation of gut microbiota and in the prevention/treatment of disease, as well as the potential of using nanotechnology to facilitate the targeting of these compounds and the limitations of using these systems for such applications.

后生物:肠道微生物群的调节和与纳米技术相关的潜力。
后生物制剂是含有对宿主有直接或间接有益作用的无生命微生物或其成分的制剂,可以包括许多不同的成分,如短链脂肪酸、细菌裂解物、无细胞培养上清、细胞壁片段、酶和外多糖。尽管后生物制剂对人体有许多好处,但由于不利的药代动力学、低生物利用度、非选择性药理作用、不良适口性和令人不快的气味,它们的使用受到限制。基于纳米技术的递送系统的发展可能是一个重要的工业工具,以增强这些药物的选择性作用和提高其治疗效果,特别是在制药和食品部门。在制药行业,一些基于纳米技术的给药系统已经被FDA批准并成功上市,证明了它们的临床和工业可行性,如Abraxane®,Doxil®(或Caelyx®),Onivyde®,Marqibo®和Vyxeos®。在食品行业,Driphorm®(用于在食品中有效输送维生素D的纳米结构脂质乳液)等产品说明了纳米技术如何以具体方式应用于功能性食品和营养保健品的开发,为技术创新、附加值和健康促进做出贡献。然而,尽管纳米技术在给药后生物制剂方面是一个新兴的创新领域,具有很有前景的临床前研究,但缺乏统一的临床或商业数据意味着这一主题需要扩大,以实现标准化和临床验证。这篇综述旨在强调后生物制剂在调节肠道微生物群和预防/治疗疾病中的重要性,以及利用纳米技术促进这些化合物靶向的潜力和使用这些系统进行此类应用的局限性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Probiotics and Antimicrobial Proteins
Probiotics and Antimicrobial Proteins BIOTECHNOLOGY & APPLIED MICROBIOLOGYMICROB-MICROBIOLOGY
CiteScore
11.30
自引率
6.10%
发文量
140
期刊介绍: Probiotics and Antimicrobial Proteins publishes reviews, original articles, letters and short notes and technical/methodological communications aimed at advancing fundamental knowledge and exploration of the applications of probiotics, natural antimicrobial proteins and their derivatives in biomedical, agricultural, veterinary, food, and cosmetic products. The Journal welcomes fundamental research articles and reports on applications of these microorganisms and substances, and encourages structural studies and studies that correlate the structure and functional properties of antimicrobial proteins.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信